What is the recommended dosing, administration schedule, monitoring, and contraindications for romosumab (Evenity) therapy?

How to Use Romosozumab (Evenity)

Romosozumab should be administered as 210 mg subcutaneously once monthly for exactly 12 months in postmenopausal women with osteoporosis at very high fracture risk, followed by mandatory sequential therapy with an antiresorptive agent. 1

Patient Selection and Indications

Romosozumab is reserved for postmenopausal women with osteoporosis at very high risk for fracture, specifically defined as 1:

• History of osteoporotic fracture (ideally within 2 years)
• Multiple risk factors for fracture
• Patients who have failed or are intolerant to other osteoporosis therapy

The 2023 ACP guidelines position romosozumab as a conditional recommendation for females with primary osteoporosis at very high fracture risk, not as first-line therapy 2. However, the FDA label supports its use in this high-risk population 1.

Critical Contraindications

Do NOT initiate romosozumab in patients with 1:

• Myocardial infarction or stroke within the preceding year (BLACK BOX WARNING)
• Pre-existing hypocalcemia (must be corrected first)
• History of systemic hypersensitivity to romosozumab (angioedema, erythema multiforme, urticaria)

Discontinue immediately if the patient experiences MI or stroke during therapy 1.

Carefully weigh cardiovascular risk factors before initiating—while the FRAME trial showed balanced cardiovascular events 3, the ARCH trial demonstrated higher cardiovascular events compared to alendronate 4, 5.

Dosing and Administration

Standard Regimen

• Dose: 210 mg total = TWO separate 105 mg/1.17 mL prefilled syringes 1
• Frequency: Once monthly for exactly 12 months maximum 1
• Route: Subcutaneous injection in abdomen, thigh, or upper arm 1
• Administration: Must be given by a healthcare provider 1

Preparation Steps 1

1. Remove two syringes from refrigerator; allow to reach room temperature for at least 30 minutes
2. Visually inspect: solution should be clear to opalescent, colorless to light yellow
3. Prepare two separate injection sites (rotate sites with each dose)
4. Clean sites with alcohol; let dry
5. Remove gray needle cap only when ready to inject (do not recap)
6. Inject first syringe subcutaneously, then immediately repeat with second syringe
7. Dispose in sharps container

If dose is missed: Administer as soon as possible, then resume monthly schedule from that date 1.

Mandatory Supplementation and Monitoring

Required Supplementation

• Calcium and vitamin D supplementation is mandatory throughout treatment 1
• Correct any hypocalcemia before initiating therapy 1

Monitoring

• Baseline serum calcium (correct if low)
• Cardiovascular risk assessment before initiation
• Monitor for injection site reactions (occur in 4-5% of patients) 4
• Watch for hypersensitivity reactions

Sequential Therapy: The Critical Component

The anabolic effect of romosozumab wanes after 12 months; therefore, duration must be limited to 12 monthly doses 1. This is non-negotiable.

After completing 12 months of romosozumab, patients MUST transition to an antiresorptive agent to preserve gains and prevent rebound fractures 2, 1. Options include:

• Denosumab (most studied sequential agent) 3
• Bisphosphonates (alendronate) 2

The FRAME trial demonstrated that romosozumab followed by denosumab resulted in 75% lower vertebral fracture risk at 24 months compared to placebo-denosumab 3. Sequential therapy is essential—failure to follow with antiresorptive therapy risks serious rebound and multiple vertebral fractures 2.

Recent data suggests 3 months of romosozumab followed by 9 months of denosumab may be non-inferior to 12 months of romosozumab for BMD increases 6, though this abbreviated approach requires further validation before routine use.

Efficacy Expectations

Romosozumab demonstrates superior outcomes compared to other agents:

• 73% reduction in vertebral fractures at 12 months vs placebo 3
• 36% reduction in clinical fractures at 12 months 3
• Superior to alendronate for fracture reduction and BMD gains 4
• More potent BMD increases than teriparatide in bisphosphonate-pretreated patients 7

Safety Profile and Adverse Events

Common Adverse Events 4, 5

• Injection site reactions (4-5%)
• Arthralgia
• Headache
• Muscle cramps/pain

Serious Adverse Events

• Cardiovascular events: Conflicting data, but BLACK BOX WARNING exists 1, 4
• Atypical femoral fractures (rare—1 case in FRAME trial) 3
• Osteonecrosis of the jaw (rare—2 cases in FRAME trial) 3
• Hypercalcemia risk lower than PTH analogs 8

Key Pitfall to Avoid

Do not use romosozumab in patients with recent cardiovascular events or high cardiovascular risk—the cardiovascular safety signal, while debated, warrants caution 1, 4, 5.

Treatment Sequence Considerations

Optimal positioning in treatment algorithm:

• Best as first-line therapy in very high-risk patients without cardiovascular contraindications 9
• More effective when used before rather than after bisphosphonates 4
• Always follow with potent antiresorptive (denosumab preferred based on trial data) 3, 10

Real-world evidence shows romosozumab provides greater fracture reduction than PTH analogs, particularly in women ≥65 years with prior fractures 8.